Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 2/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.96 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.96 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.96 |
| ▸ | PGR | P06401 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | SHBG | P04278 | 2/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.96 |
| ▸ | MAPT | P10636 | 2/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | AR | P10275 | 1/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL10292969 | 0.98 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL19465688 | 0.98 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL10261067 | 0.98 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL6932400 | 0.98 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL143923 | 0.98 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL24900238 | 0.98 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL1688689 | 0.98 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL5699764 | 0.98 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL12737556 | 0.98 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL1560948 | 0.98 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113559105-A | Treatment of resistant acne | 维奥姆治疗有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-106163526-B | Treatment of resistant acne | 维奥姆治疗有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-1379197-A4 | DELIVERY OF DRUGS FROM SUSTAINED RELEASE DEVICES IMPLANTED IN MYOCARDIAL TISSUE OR IN THE PERICARDIAL SPACE | DURECT CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080095824-A1 | Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space | DURECT CORPORATION | 2008-04-24 | — | — | US | disclosed |
| EP-1379197-A1 | DELIVERY OF DRUGS FROM SUSTAINED RELEASE DEVICES IMPLANTED IN MYOCARDIAL TISSUE OR IN THE PERICARDIAL SPACE | Durect Corporation (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030009145-A1 | Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space | DURECT CORPORATION | 2003-01-09 | — | — | US | disclosed |
| WO-2002076344-A1 | DELIVERY OF DRUGS FROM SUSTAINED RELEASE DEVICES IMPLANTED IN MYOCARDIAL TISSUE OR IN THE PERICARDIAL SPACE | DURECT CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080095824-A1 | Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space | TNNT2, TNNC1, TNNI3 | NR3C1 1436/4885HIF1A 857/4885HSD17B10 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.